Canaccord lowered the firm’s price target on Progyny to $37 from $46 and keeps a Buy rating on the shares. The firm lowered its target following a 1Q miss versus revenue estimates, 2Q guide below expectations, and annual downward guidance revision.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Progyny, Inc. Announces Details for Its First Quarter 2024 Results Report
- Progyny and Fertility Matters Canada Recognize Canadian Fertility Awareness Week to Advocate for Expanded Access to Family Building Care
- Progyny and RESOLVE to Honor National Infertility Awareness Week® with Events Spanning Coast to Coast
- Progyny, Inc. to Present at KeyBanc Life Sciences & MedTech Investor Forum
- Progyny, Inc. to Present at Barclays 26th Annual Global Healthcare Conference